By Fineline Cube 
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company’s financial capacity to further its research and development efforts in innovative oncology treatments.
Ascentage Pharma’s Global Biopharma Ambitions
Ascentage Pharma, a global biopharmaceutical company dedicated to the research and development of innovative drugs for the treatment of tumors, made its debut in Hong Kong in October 2019. The company has since been at the forefront of cancer therapy innovation, with a rich product pipeline targeting key proteins in the apoptosis pathway, including Bcl-2, IAP, and MDM2-p53.
Ongoing Clinical Trials and Pipeline Expansion
Currently, Ascentage Pharma has over 40 clinical trials in progress across China, the US, Australia, and Europe. These trials are indicative of the company’s commitment to advancing novel therapies and improving patient outcomes in the field of oncology. The proceeds from the secondary offering on Nasdaq are expected to support the continued development of these promising drug candidates and potentially accelerate their path to market.-Fineline Info & Tech